|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-3-16
|
|
pubmed:abstractText |
SR13668 (2,10-dicarbethoxy-6-methoxy-5,7-dihydro-indolo-(2,3-b)carbazole), is a new candidate cancer chemopreventive agent under development. It was designed using computational modeling based on a naturally occurring indole-3-carbinol and its in vivo condensation products. It showed promising anti-cancer activity and its preclinical toxicology profile (genotoxicity battery and subchronic rat and dog studies) was unremarkable. However, it exhibited a very poor oral bioavailability (<1%) in both rats and dogs. Therefore, a study was initiated to develop and evaluate in dogs and non-human primates formulations with a more favorable oral bioavailability.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1109-16
|
|
pubmed:meshHeading |
pubmed-meshheading:19756605-Administration, Oral,
pubmed-meshheading:19756605-Animals,
pubmed-meshheading:19756605-Antineoplastic Agents,
pubmed-meshheading:19756605-Area Under Curve,
pubmed-meshheading:19756605-Biological Availability,
pubmed-meshheading:19756605-Carbazoles,
pubmed-meshheading:19756605-Chromatography, High Pressure Liquid,
pubmed-meshheading:19756605-Dogs,
pubmed-meshheading:19756605-Drug Screening Assays, Antitumor,
pubmed-meshheading:19756605-Fasting,
pubmed-meshheading:19756605-Injections, Intravenous,
pubmed-meshheading:19756605-Macaca fascicularis,
pubmed-meshheading:19756605-Male,
pubmed-meshheading:19756605-Metabolic Clearance Rate,
pubmed-meshheading:19756605-Molecular Structure,
pubmed-meshheading:19756605-Organic Chemicals,
pubmed-meshheading:19756605-Polyethylene Glycols
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys.
|
|
pubmed:affiliation |
Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd., Rm. 2116, Bethesda, MD 20892, USA. kapetani@mail.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
